Several new treatments are revolutionizing diabetes management, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide being highlighted potential options. Retatrutide, a twin GIP and GLP-1 target activator, exhibits significant body mass decrease and enhanced glycemic control. Cagrillintide, one GLP-1 agonist, is presently in research studi